Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

Next on the list of largest golden parachutes is Gilead’s Daniel O’Day, who would receive $80.6 million in the event of ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.